Evidence map›Paper›PMID 26495869›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2015

Absence of TGF-β Receptor Activation by Highly Purified hCG Preparations.

Hannu Koistinen, Laura Hautala, Katri Koli, Ulf-Håkan Stenman

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. hCG: Biological Functions and Clinical Applications.International journal of molecular sciences · 2017
    Review
  6. Human Chorionic Gonadotropin and Breast Cancer.International journal of molecular sciences · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hannu KoistinenDepartment of Clinical Chemistry (H.K., L.H., U.-H.S.), University of Helsinki and Helsinki University Central Hospital, 00290 Helsinki, Finland; and Research Programs Unit (K.K.), Translational Cancer Biology and Transplantation Laboratory, Haartman Institute, University of Helsinki, 00290 Helsinki, Finland.
Laura HautalaDepartment of Clinical Chemistry (H.K., L.H., U.-H.S.), University of Helsinki and Helsinki University Central Hospital, 00290 Helsinki, Finland; and Research Programs Unit (K.K.), Translational Cancer Biology and Transplantation Laboratory, Haartman Institute, University of Helsinki, 00290 Helsinki, Finland.
Katri KoliDepartment of Clinical Chemistry (H.K., L.H., U.-H.S.), University of Helsinki and Helsinki University Central Hospital, 00290 Helsinki, Finland; and Research Programs Unit (K.K.), Translational Cancer Biology and Transplantation Laboratory, Haartman Institute, University of Helsinki, 00290 Helsinki, Finland.
Ulf-Håkan StenmanDepartment of Clinical Chemistry (H.K., L.H., U.-H.S.), University of Helsinki and Helsinki University Central Hospital, 00290 Helsinki, Finland; and Research Programs Unit (K.K.), Translational Cancer Biology and Transplantation Laboratory, Haartman Institute, University of Helsinki, 00290 Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, several LH/human chorionic gonadotropin (hCG) receptor-independent activities for hCG have been described, including activation of the TGF-β receptor (TGFβR) by hyperglycosylated hCG and stimulation of trophoblast invasion. Because the hCG concentrations used in these studies have been rather high, reflecting physiological hCG levels in pregnancy, even a minor contamination with growth factors, which act at very low concentrations, may be significant. Several commercial hCG preparations have been found to contain significant amounts of epidermal growth factor (EGF), which we also confirmed here. Furthermore, we found that some hCG preparations also contain significant amounts of TGF-β1. These hCG preparations were able to activate ERK1/2 in JEG-3 choriocarcinoma cells or TGFβR in mink lung epithelial cells transfected with a reporter gene for TGFβR activation. No such activation was found with highly purified hCG or its free β-subunit (hCGβ), irrespective of whether they were hyperglycosylated or not. Taken together, our results suggest that the growth factor contaminations in the hCG preparations can cause activation of TGFβR and, at least in JEG-3 cells, MAPK signaling. This highlights the importance to carefully control for potential contaminations and that highly purified hCG preparations have to be used for biological studies.

Indexed as

Cell Line, TumorChorionic GonadotropinFemaleHumansPregnancyReceptors, Transforming Growth Factor betaSignal TransductionChorionic GonadotropinReceptors, Transforming Growth Factor beta

Identifiers

PMID26495869
PMCPMC5414661
OpenAlexW2108938199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.